Literature DB >> 6376640

Differences in complement-dependent chemotactic activity generated by bullous pemphigoid and epidermolysis bullosa acquisita immune complexes: demonstration by leukocytic attachment and organ culture methods.

W R Gammon, A O Inman, C E Wheeler.   

Abstract

Bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA) are chronic blistering diseases associated with circulating complement (C)-binding anti-basement membrane zone (BMZ) antibodies and tissue-deposited immune complexes at the BMZ. Experimental evidence supporting a role for C-activating immune complexes in the pathogenesis of dermal inflammation and blisters has been reported in BP but not in EBA. In this study tissue-deposited immune complexes composed of EBA or BP antibodies were tested for generation of C-dependent chemotactic activity and the capacity to cause dermal leukocyte infiltration and dermal-epidermal separation (DES). Chemotactic activity was measured by the leukocyte attachment (LA) method. The capacity of complexes to mediate leukocyte infiltration and DES was examined in vitro using a newly described organ culture method. The results of LA showed immune complexes formed in vivo in EBA skin or in vitro by treating normal human skin with EBA antibodies were significantly more active in mediating C-dependent chemotaxis than complexes in BP skin or those formed with BP antibodies of equivalent or higher C-binding titers. Furthermore EBA antibodies and C caused leukocyte infiltration and DES in organ culture while BP antibodies did not. These results support a role for C-binding anti-BMZ antibodies in the pathogenesis of EBA lesions and demonstrate differences in the capacity of BP and EBA immune complexes to generate C-dependent chemotactic activity. These results suggest factors in addition to C-binding titers are important in the activation of C by BP and EBA immune complexes and suggest chemotactic factors other than those derived from C activation may be important in the recruitment of leukocytes in BP.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6376640     DOI: 10.1111/1523-1747.ep12261694

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Autoantibodies to type VII collagen have heterogeneous subclass and light chain compositions and their complement-activating capacities do not correlate with the inflammatory clinical phenotype.

Authors:  K Gandhi; M Chen; S Aasi; J C Lapiere; D T Woodley; L S Chan
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  Bullous pemphigoid antigen concentration in normal human skin in relation to body area and age.

Authors:  G Hamm; K D Wozniak
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

3.  Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin.

Authors:  Cassian Sitaru; Arno Kromminga; Takashi Hashimoto; Eva B Bröcker; Detlef Zillikens
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

4.  Epitope mapping of type VII collagen. Identification of discrete peptide sequences recognized by sera from patients with acquired epidermolysis bullosa.

Authors:  J C Lapiere; D T Woodley; M G Parente; T Iwasaki; K C Wynn; A M Christiano; J Uitto
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

Review 5.  The role of complement-derived mediators in inflammatory skin diseases.

Authors:  H Tagami
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

Review 6.  Utility of immunofluorescence in dermatology.

Authors:  Varsha M Shetty; Kumudhini Subramaniam; Raghavendra Rao
Journal:  Indian Dermatol Online J       Date:  2017 Jan-Feb

7.  Complement-Activating Capacity of Autoantibodies Correlates With Disease Activity in Bullous Pemphigoid Patients.

Authors:  Roxana M Chiorean; Adrian Baican; Mayson B Mustafa; Annette Lischka; Daniel-Corneliu Leucuta; Vasile Feldrihan; Michael Hertl; Cassian Sitaru
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.